UK markets open in 2 hours 3 minutes

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
148.88+1.82 (+1.24%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close147.06
Open147.45
Bid0.00 x 800
Ask0.00 x 1300
Day's range146.84 - 149.73
52-week range109.16 - 157.00
Volume7,937,316
Avg. volume6,041,615
Market cap391.974B
Beta (5Y monthly)0.68
PE ratio (TTM)26.19
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.04 (2.75%)
Ex-dividend date24 Aug 2020
1y target estN/A
All
News
Press releases
  • TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress
    Business Wire

    TRITON Phase 3b Study Results Presented at the European Society of Cardiology Congress

    Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announced results from the Phase 3b TRITON trial, the first randomised controlled study evaluating the efficacy and safety of initial triple oral combination therapy (UPTRAVI® [selexipag], OPSUMIT® [macitentan] and tadalafil) compared to initial double oral combination therapy (placebo, macitentan and tadalafil) in newly diagnosed, treatment-naïve patients with pulmonary arterial hypertension (PAH). Study results were featured as an oral presentation as part of the digital European Society of Cardiology Congress held 29 August – 1 September 2020.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more